Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Berlin – page 31

1 770 clinical trials in Berlin, Germany across 17 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Berlin at a glance
1 770
clinical trials
  • Research sites17
Type of trial
Recruitment status
Quick filters

1 770 trials in Berlin

Open in trial search

Paroxysmal nocturnal haemoglobinuria

Recruiting

Study on the Safety and Effects of Iptacopan in Children with Paroxysmal Nocturnal Hemoglobinuria (PNH) Aged 2 to 17 Years

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Iptacopan Hydrochloride
  • Sponsor:Novartis Pharma AG

Hormone-refractory prostate cancer+1

Recruiting

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Major depression

Recruiting

Study of milsaperidone as an additional treatment for adults with Major Depressive Disorder who are already taking antidepressants

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:(1S)-1-[4-[3-[4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)PIPERIDIN-1-YL]PROPOXY]-3-METHOXYPHENYL]ETHANOL
  • Sponsor:Vanda Pharmaceuticals Netherlands B.V.

Non-small cell lung cancer metastatic

Recruiting

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:IBUZATRELVIR
  • Sponsor:Pfizer Inc.

Idiopathic pulmonary fibrosis+1

Recruiting

Long-Term Safety Study of Inhaled Pirfenidone for Patients with Progressive or Idiopathic Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Hepatoblastoma+1

Recruiting

Study on the Safety and Effectiveness of Patritumab Deruxtecan for Children with Relapsed or Refractory Hepatoblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Dexamethasone
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Recruiting

Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nvl-655
  • Sponsor:Nuvalent Inc.

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Comparison of TAK-881 and HyQvia for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Takeda Development Center Americas Inc.

Cardiac failure+1

Recruiting

Study on the Effects of CDR132L on Heart Structure and Function in Patients with Heart Failure and Left Ventricular Hypertrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

HER2 positive gastric cancer

Recruiting

Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Berlin

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on various cancer treatments, including studies of metastatic prostate cancer, colorectal cancer, and innovative approaches for breast cancer treatment.

  • Prostate Cancer Therapeutics
  • Colorectal Cancer Treatment
  • Early-Stage Breast Cancer
  • Bladder Cancer Interventions

Novel combination therapies and targeted treatments are being evaluated to improve patient outcomes across multiple cancer types.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting various viral infections, including studies on respiratory syncytial virus, cytomegalovirus, and herpes zoster.

  • RSV Vaccine Development
  • CMV Prevention
  • Yellow Fever Protection
  • Herpes Virus Management

These trials aim to enhance immune response and provide long-term protection against serious viral infections.

03 Chronic Conditions

Innovative treatments for various chronic conditions, including autoimmune dementia, hypertriglyceridemia, and studies in transplant medicine.

  • Neurological Disorders
  • Metabolic Conditions
  • Organ Transplantation
  • Women's Health

Research focuses on developing targeted therapies and improving treatment outcomes for long-term conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.